OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
January 04, 2023
Advancing the use of AI to understand the whole of a disease can reveal drug development insights that lead to drug discovery breakthroughs.
January 03, 2023
This compilation allows readers to adjust their thinking to appreciate the full impact certain select technologies will make on the industry by 2026.
Inhaled vaccines must resist degradation and penetrate the mucosal lining in the airways and lungs.
January 02, 2023
Cell and gene therapies is unequivocally viewed as the biggest opportunity in the bio/pharma space.
December 20, 2022
Sosei Heptares and Eli Lilly have entered a multi-target collaboration and license agreement in diabetes and metabolic diseases.
In this episode of the Drug Solutions Podcast, Meg Rivers discusses outsourcing strategies in biopharma with Jeff Henderson, key account manager of Vetter.
December 19, 2022
GSK and Wave Life Sciences have entered into a collaboration to drive drug discovery and development for novel genetic targets.
AbCellera and Rallybio are teaming up to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases.
December 14, 2022
Emmes’ new facility is designed to support clients conducting cell and gene therapy research worldwide.
December 12, 2022
Generate Biomedicines published a preprint describing technology that can generate novel proteins towards desired functional or other properties.